AlloVir (ALVR) Competitors

AlloVir (NASDAQ:ALVR) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Does the media prefer ALVR or ATRA?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 6 mentions for Atara Biotherapeutics and 5 mentions for AlloVir. AlloVir's average media sentiment score of 2.09 beat Atara Biotherapeutics' score of 0.35 indicating that AlloVir is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AlloVir	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Atara Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer ALVR or ATRA?

Atara Biotherapeutics received 405 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.39% of users gave Atara Biotherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.

Company	Underperform	Outperform
AlloVir	Outperform Votes 27 57.45%	Underperform Votes 20 42.55%
Atara Biotherapeutics	Outperform Votes 432 67.39%	Underperform Votes 209 32.61%

Which has more volatility and risk, ALVR or ATRA?

AlloVir has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Which has better valuation & earnings, ALVR or ATRA?

AlloVir has higher earnings, but lower revenue than Atara Biotherapeutics. AlloVir is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$0.88	-0.65
Atara Biotherapeutics	$8.57M	7.18	-$276.13M	-$25.78	-0.41

Do analysts rate ALVR or ATRA?

Atara Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 56.05%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Is ALVR or ATRA more profitable?

AlloVir has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Atara Biotherapeutics	-132.58%	N/A	-90.16%

Do institutionals and insiders hold more shares of ALVR or ATRA?

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 33.8% of AlloVir shares are owned by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Atara Biotherapeutics beats AlloVir on 10 of the 17 factors compared between the two stocks.